Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
393.2 USD | -0.08% | -0.77% | -3.29% |
Apr. 18 | Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain | MT |
Apr. 17 | UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.29% | 102B | |
+1.59% | 96.07B | |
-1.80% | 21.66B | |
-17.97% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-27.93% | 13.79B | |
-0.99% | 13.33B | |
+19.57% | 10.94B | |
-23.46% | 8.57B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Says Treatment for Pain After Certain Surgeries Met Primary Endpoint in Two Studies